MedTrace Logo

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers

NCT03641794 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2019-08-01

No results posted yet for this study

Summary

This is a double blind Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of DN1406131, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and tryptophan 2,3-Dioxygenase 2 (TDO-2) and help the human immune system attack solid tumor cells more effectively.

Conditions

Interventions

DRUG

DN1406131

IDO1 and TDO2 inhibitor

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Shanghai De Novo Pharmatech Co., Ltd.

    collaborator INDUSTRY

  • Jiangxi Qingfeng Pharmaceutical Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Qinghong Zhou · Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-07
Primary Completion
2019-05-13
Completion
2019-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03641794 on ClinicalTrials.gov